Matinas BioPharma's MAT2203 Shows Promise in Combating Severe Fungal Infections
Key Insights
Matinas BioPharma's MAT2203, an oral formulation of amphotericin B, demonstrates enhanced survival and reduced fungal burden in preclinical studies.
The Phase 2 clinical trial drug aims to provide a safer, orally bioavailable treatment option for severe fungal infections (search), addressing toxicity concerns.
Matinas BioPharma utilizes its lipid-crystal nano-particle cochleate technology to improve drug delivery and efficacy of anti-infective therapies.
Matinas BioPharma Holdings, Inc. (search) (NYSE: MTNB) is advancing its innovative anti-infective therapies, with a focus on orphan indications. The company's lead drug candidate, MAT2203, an orally-administered, encochleated formulation of amphotericin B, has shown promising results in preclinical studies, demonstrating prolonged survival and reduced fungal burden in a neutropenic mouse model of lung infection. These findings suggest the potential for MAT2203 to offer a less toxic and more effective oral treatment for severe fungal infections (search).
Addressing the Challenge of Fungal Infections
Invasive fungal infections (search) pose a significant threat, particularly to immunocompromised patients. Current treatments, such as intravenous amphotericin B, are often associated with significant toxicity, limiting their use and effectiveness. Matinas BioPharma's proprietary lipid-crystal nano-particle cochleate technology aims to overcome these limitations by enhancing the safety, tolerability, and oral bioavailability of existing drugs.
MAT2203: A Novel Oral Amphotericin B Formulation
MAT2203 is currently in Phase 2 clinical trials, evaluating its efficacy and safety in patients with severe fungal infections (search). The oral formulation offers a potential advantage over intravenous administration, improving patient convenience and reducing the risk of infusion-related reactions. The encochleated technology protects the amphotericin B from degradation in the gastrointestinal tract, allowing for efficient absorption and delivery to the site of infection.
MAT2501: Targeting Acute Bacterial Infections
In addition to MAT2203, Matinas BioPharma is also developing MAT2501, an orally-administered, encochleated formulation of amikacin. Amikacin is a broad-spectrum aminoglycoside antibiotic agent effective against acute bacterial infections (search), including non-tuberculous mycobacterium (search) (NTM) and multi-drug resistant gram-negative bacterial infections. MAT2501 is currently in Phase 1 clinical trials, following an open Investigational New Drug (IND) application.
Leveraging Innovative Technology
Matinas BioPharma's innovative approach positions the company at the forefront of developing next-generation anti-infective therapies. By leveraging its nano-encapsulation technology, Matinas BioPharma is committed to creating safer and more effective treatments for patients with serious infections.